PMC5844437_01
The tumor is composed of cells with hyperchromatic nuclei, no nucleoli, scant cytoplasm, and nuclear molding, with numerous mitoses (hematoxylin-eosin, 400x).
10.1177_2324709618760644-fig1.jpg
PMC5844437_01_10.1177_2324709618760644-fig1.jpg
fig1-2324709618760644
High-power evaluation (400x) demonstrated tumor cells with hyperchromatic nuclei, no nucleoli, scant cytoplasm, and nuclear molding, with numerous mitoses (Figure 1).
The tumor has neuroendocrine features as shown by positivity with antibodies to CD56 (400x).
10.1177_2324709618760644-fig2.jpg
PMC5844437_01_10.1177_2324709618760644-fig2.jpg
fig2-2324709618760644
The tumor has neuroendocrine features as shown by positivity with antibodies to CD5 (Figure 2) and synaptophysin (Figure 3).
The tumor has neuroendocrine features as shown by positivity with antibodies to synaptophysin (400x).
10.1177_2324709618760644-fig3.jpg
PMC5844437_01_10.1177_2324709618760644-fig3.jpg
fig3-2324709618760644
The tumor has neuroendocrine features as shown by positivity with antibodies to CD5 (Figure 2) and synaptophysin (Figure 3).
p53 mutation is shown by positive nuclear staining with antibody to p53 (400x).
10.1177_2324709618760644-fig4.jpg
PMC5844437_01_10.1177_2324709618760644-fig4.jpg
fig4-2324709618760644
The tumor is a carcinoma as evidenced by positivity with antibodies to CK7 (400x).
10.1177_2324709618760644-fig5.jpg
PMC5844437_01_10.1177_2324709618760644-fig5.jpg
fig5-2324709618760644
The tumor is a carcinoma as evidenced by positivity with antibodies to cytokeratin AE1/AE3 (400x).
10.1177_2324709618760644-fig6.jpg
PMC5844437_01_10.1177_2324709618760644-fig6.jpg
fig6-2324709618760644